Clearside Biomedical Inc.

2.66-0.1000-3.62%Vol 55.13K1Y Perf 21.53%
Apr 16th, 2021 10:34 DELAYED
BID2.65 ASK2.67
Open2.76 Previous Close2.76
Pre-Market- After-Market-
 - -%  - -
Target Price
5.83 
Analyst Rating
Moderate Buy 2.00
Potential %
123.37 
Finscreener Ranking
★★+     49.06
Insiders Trans % 3/6/12 mo.
-50/-60/-17 
Value Ranking
     42.55
Insiders Value % 3/6/12 mo.
-84/-84/-69 
Growth Ranking
★★★+     57.86
Insiders Shares Cnt. % 3/6/12 mo.
-79/-80/-60 
Income Ranking
 —    -
Market Cap152.74M 
Earnings Rating
Sell
Price Range Ratio 52W %
42.99 
Earnings Date
14th May 2021

Today's Price Range

2.562.76

52W Range

1.254.53

5 Year PE Ratio Range

-3.80-1.50

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
3.76%
1 Month
-5.48%
3 Months
-31.17%
6 Months
89.04%
1 Year
21.53%
3 Years
-73.76%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CLSD2.66-0.1000-3.62
AAPL134.10-0.4000-0.30
GOOG2 292.22-4.4400-0.19
MSFT259.42-0.0800-0.03
XOM56.55-0.4300-0.75
WFC43.150.91002.15
JNJ160.730.34000.21
FB306.42-1.4000-0.45
GE13.47-0.0800-0.59
JPM153.671.50000.99
Financial StrengthValueIndustryS&P 500US Markets
1.70
1.80
0.07
0.23
-
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
-
-140.80
-138.90
-59 955.60
-
RevenueValueIndustryS&P 500US Markets
3.80M
0.07
294.22
56.13
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.13-0.14-7.69
Q03 2020-0.14-0.0564.29
Q02 2020-0.13-0.130.00
Q01 2020-0.09-0.0722.22
Q04 2019-0.04-0.07-75.00
Q03 2019-0.16-0.17-6.25
Q02 2019-0.37-0.1559.46
Q01 2019-0.36-0.45-25.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.08-14.29Negative
6/2021 QR-0.10-11.11Negative
12/2021 FY-0.3118.42Positive
12/2022 FY-0.4315.69Positive
Next Report Date14th May 2021
Estimated EPS Next Report-0.08
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume55.13K
Shares Outstanding57.42M
Trades Count223
Dollar Volume1.64M
Avg. Volume675.89K
Avg. Weekly Volume226.11K
Avg. Monthly Volume265.99K
Avg. Quarterly Volume465.70K

Clearside Biomedical Inc. (NASDAQ: CLSD) stock closed at 2.76 per share at the end of the most recent trading day (a 3.37% change compared to the prior day closing price) with a volume of 205.20K shares and market capitalization of 152.74M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 33 people. Clearside Biomedical Inc. CEO is George Lasezkay.

The one-year performance of Clearside Biomedical Inc. stock is 21.53%, while year-to-date (YTD) performance is 0.73%. CLSD stock has a five-year performance of %. Its 52-week range is between 1.25 and 4.53, which gives CLSD stock a 52-week price range ratio of 42.99%

Clearside Biomedical Inc. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 16.71, a price-to-sale (PS) ratio of 40.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -75.13%, a ROC of -90.01% and a ROE of -174.17%. The company’s profit margin is -%, its EBITDA margin is -138.90%, and its revenue ttm is $3.80 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Clearside Biomedical Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.08 for the next earnings report. Clearside Biomedical Inc.’s next earnings report date is 14th May 2021.

The consensus rating of Wall Street analysts for Clearside Biomedical Inc. is Moderate Buy (2), with a target price of $5.83, which is +123.37% compared to the current price. The earnings rating for Clearside Biomedical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Clearside Biomedical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Clearside Biomedical Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.44, ATR14 : 0.38, CCI20 : 87.68, Chaikin Money Flow : -0.21, MACD : -0.19, Money Flow Index : 60.77, ROC : 23.21, RSI : 49.20, STOCH (14,3) : 87.30, STOCH RSI : 0.98, UO : 59.70, Williams %R : -12.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Clearside Biomedical Inc. in the last 12-months were: Charles A. Deignan (Sold 14 992 shares of value $28 185 ), Clay B. Thorp (Sold 32 873 shares of value $145 627 ), George M. Lasezkay (Sold 58 261 shares of value $121 918 ), Nancy J. Hutson (Buy at a value of $34 025), William D. Humphries (Buy at a value of $19 886)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (50.00 %)
2 (40.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (50.00 %)
3 (50.00 %)
3 (60.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.20

Clearside Biomedical Inc.

Clearside Biomedical Inc is the United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision.

CEO: George Lasezkay

Telephone: +1 678 270-3631

Address: 900 North Point Parkway, Alpharetta 30005, GA, US

Number of employees: 33

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

News

Stocktwits